FIELD: organic chemistry, medicine, biochemistry, pharmacy.
SUBSTANCE: invention relates to using 4-fluoro-N-indane-2-ylbenzamide of the formula (I) 
as a pharmaceutical agent used in stimulation of endothelial nitrogen oxide (NO) synthase (eNOS) expression and in treatment and prophylaxis of some cardiovascular diseases (for example, stenocardia, acute coronary syndrome, cardiac insufficiency, myocardium infarction, insult, thrombosis, occlusive diseases of peripheral arteries, restenosis and so on), and to pharmaceutical compositions for the same designation. Early compound of the formula (I) is used in treatment of the central nervous system diseases owing its cholinergic activity. It was shown that compound of the formula (I) enhances eNOS transcription, reduces blood pressure value reliably in rats with hyperlipoproteinemia, decreases pathological formation of neointima by two-fold and shows anti-ischemic effect.
EFFECT: valuable medicinal properties of compound.
10 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ACIDIFIED ARYLCYCLOALKYLAMINS AND THEIR APPLICATION AS PHARMACEUTICAL DRUGS | 2003 |
|
RU2337094C2 |
| COMPOSITIONS CONTAINING DPP-4 INHIBITOR FOR PREVENTION OR TREATMENT OF VALVE CALCIFICATION | 2015 |
|
RU2680527C1 |
| ACIDIFIED INDANYLAMINES AND THEIR USE AS PHARMACEUTICAL PREPARATIONS | 2002 |
|
RU2339614C2 |
| ACIDYLATED HETEROARYLCONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICAL AGENTS | 2003 |
|
RU2338743C2 |
| METHOD FOR PREDICTING THE RISK OF THROMBOTIC COMPLICATIONS OF PATIENTS WITH CARDIOVASCULAR PATHOLOGY | 2020 |
|
RU2746234C1 |
| COMPOSITION POSSESSING ENDOTHELIAL PROTECTIVE, VASODILATING AND ANGIOPROTECTIVE EFFECT | 2011 |
|
RU2464019C1 |
| METHODS FOR USE OF TRIACETYL-3-HYDROXYPHENYLADENOZINE IN TREATMENT OF INFLAMMATORY PROCESSES IN VESSELS OR IMPROVEMENT OF VESSEL ENDOTHELIUM FUNCTIONS | 2017 |
|
RU2783498C2 |
| AGENT FOR DRUG-INDUCED CORRECTION OF NITROXYDERGIC DISORDERS | 2012 |
|
RU2505297C1 |
| USING 1-(β-PHENYLETHYL)-4-AMINO-1,2,4-TRIAZOLIUM BROMIDE (HYPERTRIL) AS ACTIVE BASE OF DRUG PREPARATIONS FOR CORRECTING DYSFUNCTIONS OF NITROXYDERGIC SYSTEM OF TARGET ORGANS ACCOMPANYING HOMOCYSTEINEMIA AND ACUTE CEREBROVASCULAR DISORDERS | 2013 |
|
RU2532394C1 |
| METHOD OF TREATING METABOLIC SYNDROME WITH USING DOPAMINE RECEPTOR AGONISTS | 2008 |
|
RU2473344C2 |
